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Abstract
Insulin-like growth factor-1 (IGF-1) plays important roles in the
developing and mature retina and in pathological states
characterized by retinal neovascularization, such as diabetic
retinopathy. The effects of IGF-1 on glucose transport and
proliferation and the signal transduction pathways underlying
these effects were studied in a primary bovine retinal
endothelial cell (BREC) culture model. IGF-1 stimulated
uptake of the glucose analog 2-deoxyglucose in a dose-
dependent manner, with a maximal uptake at 25 ng/mL
(3.3 nM) after 24 h. Increased transport occurred in the
absence of an increase in total cellular GLUT1 transcript or
protein. IGF-1 stimulated activity of both protein kinase C
(PKC) and phosphatidylinositol-3 kinase (PI3 kinase), and
both pathways were required for IGF-1-mediated BREC
glucose transport and thymidine incorporation. Use of a
selective inhibitor of the b isoform of PKC, LY379196,
revealed that IGF-1 stimulation of glucose transport was
mediated by PKC-b; however, inhibition of PKC-b had no
effect on BREC proliferation. Taken together, these data
suggest that the actions of IGF-1 in retinal endothelial cells
couple proliferation with delivery of glucose, an essential
metabolic substrate. The present studies extend our general
understanding of the effects of IGF-1 on vital cellular activities
within the retina in normal physiology and in pathological
states such as diabetic retinopathy.
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Insulin-like growth factor-1 (IGF-1), a polypeptide hormone
that mediates the systemic actions of growth hormone (GH)
(Jones and Clemmons 1995), is synthesized by a variety of
cell types in the retina, including microvascular endothelial
cells, pericytes, MuÈller cells, ganglion cells, and retinal
pigment epithelium (RPE) (Lee et al. 1992). In normal
retinal physiology, IGF-1 is thought to play a role in the
development of the neuroretina in different species (Ocrant
et al. 1989; Calvaruso et al. 1996), and the expression of
IGF-1, IGF-1 binding proteins and the IGF-1 receptor in the
adult mammalian retina (Waldbillig et al. 1988, 1991;
Ocrant et al. 1989) suggests that IGF-1 participates in
processes in the mature retina as well. These processes
include interactions between the RPE and photoreceptor in
the vision signal transduction cascade (Waldbillig et al. 1988,
1991), and analogous to its role in the brain, IGF-1 also
appears to act as an anti-apoptotic factor in an experimental
model of retinal injury (Kermer et al. 2000).
In pathological states characterized by retinal neovascular-
ization, such as diabetic retinopathy (DR), accumulating
evidence suggests that IGF-1, along with vascular
endothelial growth factor (VEGF), serves as a key mediator
in disease progression. Elevated vitreal and serum concen-
trations of IGF-1 have been documented in patients with
proliferative diabetic retinopathy (PDR) (Merimee et al.
1983; Grant et al. 1986; Meyer-Schwickerath et al. 1993;
Burgos et al. 2000) and are in the range known to stimulate
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endothelial cell chemotaxis and proliferation in vitro and
in vivo (Grant et al. 1987, 1993a,b). In individuals with
diabetes diagnosed after the age of 30, elevated serum
concentrations of IGF-1 are correlated with an increased
frequency of PDR (Dills et al. 1991). There has not,
however, been universal agreement among clinical studies
investigating the relationship of serum IGF-1 concentrations
and PDR (Hyer et al. 1988; Arner et al. 1989; Lee et al.
1994). In contrast, pituitary ablation (Poulsen 1953) and
growth hormone de®ciency (Merimee 1978; Alzaid et al.
1994) have been associated with a lower risk of DR, and in
experimental models of proliferative retinopathy, mice with
decreased circulating GH and IGF-1 due to either the
expression of a GH antagonist transgene or the adminis-
tration of an inhibitor of GH fail to develop retinal
neovascularization in response to retinal hypoxia (Smith
et al. 1997).
IGF-1 is known to have direct mitogenic effects on
endothelial cells, including increased endothelial prolifera-
tion (King et al. 1983; Grant et al. 1993b), chemotaxis
(Grant et al. 1987), and angiogenesis (Grant et al. 1987,
1993b), both in vitro and in vivo. Although the signaling
pathways underlying the mitogenic effects of IGF-1 have
been described in a variety of cells of non-endothelial origin
(Butler et al. 1998), there are signi®cant differences in the
signaling pathways in which IGF-1 acts in different cell
types (Petley et al. 1999), and the precise molecular
events through which IGF-1 stimulates endothelial cell
proliferation have not been elucidated.
Similar to the endothelial cells comprising the blood±
brain barrier, the endothelial cells of the retinal micro-
vasculature are characterized by intercellular tight junctions
(zonulae occludens) and a lack of fenestrations (Cunha-Vaz
1976). These characteristics of the so-called inner blood±
retinal barrier (BRB) prevent the passive diffusion of polar
compounds from the blood into the neuroretina (Cunha-Vaz
1976). Delivery of the essential substrate glucose across the
inner BRB occurs via a speci®c facilitated transport process
mediated by the sodium-independent glucose transporter
GLUT1 (Harik et al. 1990; Takata et al. 1990; Mantych et al.
1993; Kumagai et al. 1994). Modulation of glucose transport
by changes in inner BRB GLUT1 at this critical interface
may therefore have direct effects on neuroretinal function,
since the neuroretina, like all neural tissue, is absolutely
dependent on a constant supply of glucose for normal
metabolism (Cunha-Vaz 1976).
In primary bovine retinal endothelial cell (BREC)
cultures, Takagi and coworkers have demonstrated that
hypoxia increases endothelial cell glucose transport via
up-regulation of GLUT1 mRNA and protein (Takagi et al.
1998). We have recently shown that VEGF, a potent retinal
endothelial cell mitogen, stimulates glucose transport in
BREC via activation of the b isoform of protein kinase C
(Sone et al. 2000). Unlike the effects of hypoxia, however,
this enhancement of glucose uptake is not due to increases in
total cellular abundance of GLUT1; rather, it is due to
VEGF-induced translocation of pre-existing cytosolic trans-
porters to the endothelial plasma membrane (Sone et al.
2000).
The aim of the present study was two-fold: ®rst, to
investigate the effects of IGF-1 on retinal endothelial
glucose transport and GLUT1 expression, and, second, to
determine whether the effects of IGF-1 on retinal endothelial
cell glucose transport and proliferation are mediated through
similar signal transduction pathways. We report that IGF-1
enhances retinal endothelial cell glucose transport and
proliferation via phosphatidylinositol-3 kinase (PI3 kinase)
and PKC; however, IGF-1-mediated increases in glucose
transport, and not endothelial cell proliferation, are mediated
by the b isoform of PKC.
Materials and methods
Bovine retinal endothelial cell (BREC) cultures
BREC cultures were established from fresh calf eyes as
described previously (Sone et al. 2000) and grown in Dulbecco's
modi®ed Eagle's medium (DMEM, GIBCO, Grand Island, NY,
USA) with 10% fetal calf serum (FCS), endothelial growth
supplement (EGS, 100 mg/mL, Boehringer Mannheim, Indianapolis,
IN, USA), heparin (88 mg/mL), and antibiotic-antimycotic
solution (Sigma, Saint Louis, MO, USA) on ®bronectin-coated
dishes under 5% CO2 at 378C. For all experiments, the BREC
cultures were serum-deprived (0.5% FCS) for 16 h prior to the
addition of growth factor, as described previously. (Sone et al.
2000)
For experiments involving PKC inhibitors, designated cultures
were pretreated for 1 h at 378C with either calphostin C (100 nm),
GF109203X (5 mm, both from Sigma) or the b-selective inhibitor,
LY379196 (kindly provided by Dr Kirk Ways, Eli Lilly & Co.,
Indianapolis, IN, USA). LY379196 has selective inhibitory effects
on PKC-bI and bII isoforms with ED50 values of 0.05 and 0.03 mm,
respectively (Sone et al. 2000). At 600 nm, LY379196 demon-
strates generalized inhibition of all typical PKC isoforms (a, bI, bII
and d); at 30 nm, LY379196 has bI- and bII-selective inhibition
(Sone et al. 2000). Therefore, concentrations of 600 nm and 30 nm
were used for generalized and PKC-b-selective inhibition,
respectively. The inhibitory pro®les for LY379196 for typical and
atypical PKC isoforms and related kinases have been published
previously (Sone et al. 2000). For experiments involving inhibition
of PI3 kinase, designated cultures were pretreated with either
wortmannin (100 nm, Sigma) or LY294002 (Calbiochem, San Diego,
CA, USA) before addition of growth factor. Because wortmannin is
unstable in aqueous solutions (Yano et al. 1993), the media of the
appropriate cultures were changed every 6 h to fresh media with
IGF-1 with or without wortmannin during prolonged incubations.
Media from control cultures were changed at the same intervals
to fresh media without IGF-1 or inhibitor. Effects of the various
inhibitors on cell viability were assessed by visual assessment and
comparison of cell morphology between treated and untreated
groups at the end of the treatment period and by a MTT-based cell
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viability assay (Sigma) on cultures in the presence of maximum
concentrations used for each inhibitor for a 24-h period. The cell




2-Deoxyglucose transport studies were performed according to the
methods of Tai et al. (1990) with minor modi®cations. Brie¯y, the
media from the BREC cultures was aspirated and replaced with
low-calcium Kreb's Ringers phosphate buffer containing 1%
bovine serum albumin (KRP-BSA), and the cultures were incubated
at 378C for 30 min in order to deplete intracellular glucose. After
two 5-min washes with KRP-BSA, the cultures were incubated with
0.25 mCi of the glucose analog 2-[1,2-3H(N)]-deoxy-d-glucose
([3H]2DG, speci®c activity 25 Ci/mmol, Amersham, Piscataway,
NJ, USA) in 1 mL of KRP-BSA for 3 min at room temperature.
Preliminary studies by our laboratory demonstrated that [3H]2DG
uptake was linear in BREC cultures between 2 and 10 min under
these conditions (data not shown). To assess non-speci®c binding,
parallel cultures were preincubated with KRP-BSA containing
40 mm cytochalasin-B (Sigma) for 5 min at room temperature,
followed by incubation with the [3H]2DG solution containing
cytochalasin-B. The assay was terminated by rapid aspiration of the
radioisotope solution, followed by repeated washes with ice-cold
0.2 mm phloretin (Sigma) in KRP without BSA. Cells were
solubilized in 1% sodium dodecyl sulfate (SDS), 0.1 m NaOH at
RT for 30 min. Protein was measured by a Pierce BCA assay
(Pierce Chem. Co., Rockford, IL, USA). 3H was measured by liquid
scintillation counting on a Tri-Carb Scintillation Counter (Packard
Instruments, Downers Grove, IL, USA). Results were expressed in
pmol [3H]2DG per mg protein per min. For each experiment,
n  4±5 cultures in each group.
3-O-Methylglucose (3MG) transport studies
3-O-Methylglucose (3MG) transport studies were performed on
BREC cultures as described previously (Sone et al. 2000) and were
expressed as the zero-trans initial uptake rate of [14C]3MG in pmol
per mg protein per s. For each experiment, n  5±6 cultures in
each group.
Thymidine incorporation studies
Endothelial cell proliferation was determined by the incorporation
of [3H]thymidine, by the method of Yano et al. (1999) with minor
modi®cations. Brie¯y, BREC cultures were seeded in equal density
and grown to 60% con¯uence in ®bronectin-coated 35-cm2 tissue
culture dishes. Following overnight serum deprivation, the media was
exchanged with fresh medium with or without growth factors and
corresponding inhibitors and containing 0.66 mCi/mL [3H]thymidine
(Amersham). After 24 h, the medium was aspirated, and cultures
were washed with cold PBS. The cells were incubated twice for
10 min in 5% trichloroacetic acid (TCA, Sigma), solubilized in
1 mL 0.1N NaOH, 1% SDS lysis buffer, and 3H was measured by
liquid scintillation counting.
Western blotting analysis
Western blotting analysis was performed for GLUT1 on 25-mg
aliquots of BREC whole cell lysates as described previously (Sone
et al. 2000). The anti-GLUT1 antiserum used for western blotting
was a rabbit polyclonal antiserum directed against puri®ed human
erythrocyte glucose transporter (a kind gift of Dr Christin Carter-
Su, University of Michigan) at a concentration of 1 : 10 000.
Northern blotting analysis
Northern blotting analysis was performed on 20 or 25 mg of total
RNA extracted from semicon¯uent control or IGF-1-treated BREC
cultures. Northern blotting for GLUT1 using a 512-kb Pst1 frag-
ment of bovine blood±brain barrier glucose transporter cDNA
(provided by Dr RubeÂn J. Boado, UCLA School of Medicine) was
performed as described previously (Sone et al. 2000). GLUT1
northern blots were normalized by repeat hybridization with a
32P-labeled mouse actin cDNA, as described previously (Sone et al.
2000). Quanti®cation of autoradiograms was performed using NIH
Image software and was normalized against the signal for actin.
Assay of PKC activity
Assay of PKC activity was performed in permeabilized cells
according to the methods of Heasley and Johnson with modi®ca-
tions (Heasley and Johnson 1989). Brie¯y, subcon¯uent BREC
cultures were grown in ®bronectin-coated 6-well culture dishes,
and after serum deprivation, cultures were incubated with and
without IGF-1 in the presence and absence of inhibitors for 15 min
at 378C. After incubation, the cells were washed once with DMEM
containing 20 mm HEPES (pH 7.4) and incubated in a salt solution
(137 mm NaCl, 5.4 mm KCl, 0.3 mm sodium phosphate, 0.4 mm
potassium phosphate, 1 mg/mL glucose, 20 mm HEPES, pH 7.2)
containing 25 mg/mL of puri®ed digitonin (Calbiochem, La Jolla,
CA, USA), 100 mm ATP, 14 mCi/mL of [g-32P]ATP (approxi-
mately 400 cpm/pmol or 1.8  105 mCi/pmol, Dupont-NEN,
Boston, MA, USA) and 300 mm of the speci®c PKC substrate
KRTLRR (Bachem, Torrance, CA, USA) for 15 min at 308C. In
previous experiments, PKC activity was linear between 10 and
30 min in BREC cultures under these conditions (data not shown).
At the end of the incubation, 40-mL aliquots of the reaction mixture
were spotted on Whatman P-81 phosphocellulose discs (Fischer
Scienti®c, Pittsburg, PA, USA) and air-dried for at least 10 min.
The discs were washed three times in 75 mm phosphoric acid,
followed by one wash in sodium phosphate (pH 7.5). Radioactivity
on the ®lters was measured by scintillation counting, and the
activity was normalized for protein concentrations measured in
parallel cultures under each experimental condition.
Phosphatidylinositol-3-kinase (PI3 kinase) activity assay
PI3 kinase activity assay was performed on semicon¯uent BREC
cultures after overnight serum deprivation and treatment with or
without IGF-1 (25 ng/mL) at 378C for 10 min in the presence or
absence of the PI3 kinase inhibitor wortmannin, according to the
methods of Tsakiridis et al. (1995).
Immunoprecipitation of IRS-1
After treatment, the cells were immediately washed twice with ice-
cold Buffer A (20 mm Tris, 137 mm NaCl, 1 mm MgCl2, 1 mm
CaCl2, and 1 mm sodium orthovanadate, pH 7.5) and lysed in
0.500 mL of Lysis Buffer [Buffer A plus 1% Nonidet NP-40, 10%
glycerol, 2 mm phenylmethylsulfonyl ¯uoride (PMSF), 1 mm
aprotinin, 1 mm leupeptin, 1 mm pepstatin and 2 mm E-64 (Sigma)]
on ice for 30 min with frequent gentle mixing. The lysates were
collected, the proteins measured, and immunoprecipitation for
IRS-1 was performed on 500-mg aliquots of lysates with 2 mg of
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anti-IRS-1 antibody (Upstate Biotechnologies, Inc. Lake Placid,
NY, USA) overnight at 48C with mixing. Following incubation,
60 mL of a 25% Protein A agarose slurry was added, followed by
mixing for 1 h at 48C. The immunoprecipitates were collected by
centrifugation, washed twice each with Wash Buffer I (20 mm Tris,
1% NP-40, 1 mm sodium orthovanadate and protease inhibitors),
Buffer II (100 mm Tris, 500 mm lithium chloride, 1 mm sodium
orthovanadate and protease inhibitors) and Buffer III (10 mm Tris,
100 mm NaCl, 1 mm EDTA, 1 mm sodium orthovanadate and
protease inhibitors), and were pelleted by centrifugation.
PI3 kinase assay
The kinase reaction was performed on the immunoprecipitates
by the addition of 26 mL of a solution containing ®nal concentra-
tions of 13.8 mm MgCl2, 0.156 mm ATP, 15 mCi [g-
32P]ATP
(3000 Ci/mmol, Dupont-NEN) and 40 mg of l-a-phosphatidylino-
sitol (Avanti Polar Lipids, Alabaster, AL, USA) resuspended by
sonication in 10 mL of 10 mm Tris and 1 mm EGTA. The reaction
was terminated by the addition of 20 mL of 1 m HCl, and lipids were
extracted with 160 mL of chloroform : methanol (1 : 1). Aliquots of
75 mL of the aqueous phase were loaded on an oxaloacetate-coated
HPTLC silica glass plate (EM Science, Cincinnati, OH, USA), and
a 50-mg of phosphatidylinositol 3-phosphate (PI3P) standard
(Matreya Inc., Pleasant Gap, PA, USA) suspended in CHCl3 was
loaded for comparison. Lipids were separated by chromatography
in chloroform : methanol : H2O : NH4OH at a 60 : 47 : 11.6 : 2
ratio, after which the plate was dried and wrapped in plastic wrap.
Autoradiography was performed at room temperature. The PI3P
standard was visualized by ultraviolet light after treating the TLC
plate with primulin-acetone, and quanti®cation of the labeled
reaction products was performed by scintillation counting of bands
excised from the TLC plates.
Protein measurements
Protein concentrations in all experiments were determined by a
bicinchoninic acid (BCA) assay (Pierce). For western blot samples,
b-mercaptoethanol was added after protein measurement (®nal
concentration of 5%).
Statistical analysis
All results are expressed as mean ^ SEM. Comparisons between
control and IGF-1 treated cultures for transport assays, western blot
analyses, and northern blot analyses were performed by analysis of
variance (anova) or Student's t-test, as appropriate. All transport
and thymidine incorporation assays and PKC and PI3 kinase
activity assays were performed a minimum of 2±4 times, and
western and northern blot analyses were repeated a minimum of
three times on separate cell cultures. p , 0.05 was considered
statistically signi®cant for all experiments.
Results
Exposure of BREC cell cultures to increasing concentrations
of recombinant IGF-1 for 24 h resulted in an increase in
2DG uptake in a dose-dependent manner (Fig. 1a), with a
maximal effect at 25 ng/mL (3.3 nm) at 24 h. Time course
studies of increasing duration using 50 ng/mL IGF-1
revealed an increase in 2DG uptake at 12 h of exposure,
with a maximum uptake at 24 h (data not shown). Because
2-deoxyglucose is both transported and phosphorylated
within the cell (Sokoloff et al. 1977), the increase in 2DG
accumulation measured in the assay could be the result of
an increase in hexokinase activity by IGF-1 rather than an
IGF-1-stimulated increase in transport per se. To examine
this possibility, the initial uptake rate of [14C]labeled 3-O-
methylglucose (3MG), a glucose analog that is transported
into, but not metabolized within, cells was measured. The
initial uptake rate of [14C]3MG approximately doubled
in response to 25 ng/mL of IGF-1 after 24 h
(0.76 ^ 0.14 pmol/mg/s in IGF-1-treated cultures versus
0.38 ^ 0.09 pmol/mg/s in controls, p  0.02, Fig. 1b). This
increase in 3MG uptake was comparable to the increase in
2DG uptake seen in identically treated cultures and con-
®rmed that the increase in 2DG uptake after treatment with
IGF-1 re¯ected an increase in glucose transport in BREC in
response to IGF-1.
Exposure to 25 ng/mL caused a modest (25±35%) but
signi®cant increase in speci®c PKC activity in the BREC
cultures (Fig. 2a). PKC activation was inhibited by treat-
ment with the general PKC inhibitor GF109203X (5 mm,
Fig. 1 Effects of IGF-1 on BREC glucose transport. (a) Represen-
tative [3H]2-deoxyglucose uptake assay of treatment of BREC cul-
tures with increasing concentrations of recombinant IGF-1. n  4±5
in each group, *p , 0.002 and ²p , 0.0001 compared with control
(0). (b) Representative graph of initial [14C]3-O-methylglucose
uptake rates of BREC cultures without and with treatment with IGF-1
(25 ng/mL, 24 h.). n  6 in each group, p  0.02 compared with
control.
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Fig. 2a). Treatment of the cultures with the inhibitor in the
absence of IGF-1 had no effect (Fig. 2a). In order to
determine whether IGF-1 enhancement of BREC glucose
transport was mediated by PKC, a series of experiments
employing selective PKC inhibition was performed. Treat-
ment of BREC cultures with the general PKC inhibitors
calphostin C (100 nm) and GF 109203X (5 mm) completely
abrogated the increase in 2DG uptake in response to IGF-1
(Figs 2b±c). Treatment of control cultures with either
inhibitor alone had no effect on 2DG uptake (Figs 2b±c).
The b isoform of PKC has been proposed to be a common
effector pathway in the development of diabetic complica-
tions, including retinopathy (Ishii et al. 1996; King et al.
1997). In order to determine whether IGF-1-stimulated
BREC glucose transport was mediated by PKC-b, BREC
cultures were incubated with IGF-1 in the presence and
absence of LY379196 at general PKC and PKC-b-selective
concentrations (600 nm and 30 nm, respectively). As is seen
in Fig. 2(d), general and PKC-b-selective inhibition com-
pletely abolished IGF-1-stimulated increases in 2DG uptake.
Treatment of the BREC cultures with the inhibitor alone at
either concentration had no effect (data for 30 nm not
shown).
In a variety of cell types, the mitogenic effects of IGF-1
are mediated by PI3 kinase (Jones and Clemmons 1995).
Exposure of BREC cultures to IGF-1 (25 ng/mL) resulted in
a three-fold increase in PI3 kinase activity (Fig. 3a), as
evidenced by the increase in 32P-labeled phosphatidylino-
sitol-3-phosphate (PI3P) on thin layer chromatography
(Fig. 3a). This increased activity, as well as the basal
Fig. 2 Effects of IGF-1 on BREC PKC activity. (a) PKC activity
assay on permeabilized cells. Semi-con¯uent BREC cultures were
incubated with and without IGF-1 (25 ng/mL) for 15 min in the pre-
sence and absence of the general PKC inhibitor GF 109203X (5 mM)
and phosphorylation of a PKC-speci®c substrate was assayed as
described in Materials and methods. The results are expressed as a
percentage of control PKC activity and represent the mean and SE
of four independent experiments with duplicate samples in each
experiment. *p , 0.02 compared with control; ²p not signi®cant com-
pared with control. (b)±(d) Effects of PKC inhibition on IGF-1-mediated
BREC glucose transport. Representative 2-deoxyglucose uptake
assays of control (without IGF-1) or IGF-1-treated (25 ng/mL, 24 h)
BREC cultures in the presence or absence of general (calphostin C,
GF 109203X) or b-selective (LY379196) PKC inhibitors. (b) Calphostin
C. *p , 0.05 compared with control; p not signi®cant compared with
control. (c) GF 109203X. *p , 0.01 compared with control; ²p not
signi®cant compared with control: ²p , 0.02 compared with control.
(d) LY379196, at generalized (600 nM) or b-selective (30 nM) PKC
inhibitory concentrations. *p , 0.01 compared with control; ²p not
signi®cant compared with control.
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activity, was suppressed by treatment with the PI3 kinase
inhibitor wortmannin (100 nm, Fig. 3a). Treatment of
cultures with wortmannin (100 nm) completely abolished
IGF-1-stimulated glucose transport (Fig. 3b). Furthermore,
treatment with increasing concentrations of another, struc-
turally unrelated PI3 kinase inhibitor, LY294002, resulted
in a dose-dependent decrease in 2DG uptake (Fig. 3b).
Treatment of the cultures with increasing concentrations of
LY294002 alone also signi®cantly depressed 2DG uptake
(Fig. 3b), an observation that supported the results of the PI3
kinase activity assay (Fig. 3a), which suggested that basal,
as well as IGF-1-stimulated, glucose transport was mediated
by PI3 kinase.
To determine whether the effects of IGF-1 on stimulating
BREC glucose transport were due to an increase in the
abundance of the sodium-independent glucose transporter,
GLUT1, northern and western blotting analyses for GLUT1
were performed on IGF-1-treated BREC cultures. A 24-h
exposure of BREC cultures to IGF-1 at concentrations found
to stimulate glucose transport (25 ng/mL) had no effect on
the abundance of total cellular GLUT1 protein (Fig. 4a). In
addition, quanti®cation of northern blots of total RNA from
cultures with or without with IGF-1 for durations of up to
24 h showed no effect of IGF-1 on the abundance of BREC
GLUT1 mRNA (Fig. 4b).
As has been previously shown by other investigators
(King et al. 1983; Grant et al. 1993b), IGF-1 increased
BREC proliferation, as evidenced by an increase in
[3H]thymidine incorporation, in a dose±response manner
(Fig. 5a). Inhibition of PKC by treatment of the BREC
cultures with GF109203X inhibited IGF-1 stimulated
proliferation in a dose±response manner (Fig. 5b). Further-
more, treatment with GF 109203X alone signi®cantly
suppressed thymidine incorporation in the absence of
IGF-1 treatment, which suggested that PKC mediates both
basal and IGF-1-stimulated BREC proliferation. Interest-
ingly, although the b-selective PKC inhibitor LY379196
suppressed thymidine incorporation at concentrations which
are known to inhibit all typical PKC isoforms (600 nm,
Fig. 5c), treatment of the BREC cultures with IGF-1 in the
presence of LY379196 at b-selective concentrations (30 nm)
had no effect (Fig. 5c versus Fig. 2c).
With regards to the role of PI3 kinase in mediating BREC
proliferation, treatment of the BREC cultures with IGF-1 in
the presence of the PI3 kinase inhibitor wortmannin (100 nm)
signi®cantly suppressed IGF-1-stimulated increases in thymi-
dine incorporation (Fig. 6a); wortmannin alone had no
effect (Fig. 6a). Similarly, exposure of the cultures to IGF-1
in the presence of increasing concentrations of the PI3
kinase inhibitor LY294002 (0.5±20.0 mm) resulted in
suppression of both IGF-1-stimulated and basal thymidine
incorporation in a dose±response manner (Fig. 6b).
As described above, exposure to IGF-1 stimulated both
PKC and PI3 kinase in primary BREC cultures (Figs 2a and
3a). In order to clarify the relationship between these two
signaling pathways, PKC and PI3 kinase activity assays
were performed in the presence and absence of PI3 kinase
and PKC inhibitors, respectively. As seen in Fig. 7(a), pre-
treatment of BREC with the PI3 kinase inhibitor, wortman-
nin (100 nm), abolished the ability of IGF-1 to stimulate
PKC activity. In contrast, prior exposure of BREC to the
Fig. 3 Effects PI3 kinase on IGF-1-mediated BREC glucose trans-
port. (a) Representative PI3 kinase assay of BREC with and without
stimulation by IGF-1 (25 ng/mL) for 10 min in the presence and
absence of the PI3 kinase inhibitor wortmannin (100 nM) as
described in Materials and methods. The migration of the PI3P stan-
dard is noted on the right. (b) and (c) Representative 2-deoxyglu-
cose uptake assays of control (without IGF-1) or IGF-1-treated
(25 ng/mL, 24 h) BREC cultures in the presence or absence of the
selective PI3 kinase inhibitors wortmannin (b) and LY294002 (c).
*p  0.05, ²p not signi®cant compared with control. LY294002 at
increasing concentrations (0±20 mM). *p  0.003 compared with
control; ²p not signi®cant compared with control; ³p , 0.002 com-
pared with control.
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selective PKC inhibitor, GF 109203X (5 mm), had no effect
on PI3 kinase activity (Fig. 7b). These results suggested that
PI3 kinase is upstream from PKC in signaling by IGF-1.
Wortmannin or GF109203X alone had no effect on PKC or
PI3 kinase activity, respectively (data for wortmannin not
shown).
There were no morphological differences or differences in
cell viability, as assessed by an MTT-based viability assay,
between BREC cultures with and without treatment with
the maximal concentrations of the inhibitors of PKC
(GF109203X and LY379196) or of PI3 kinase (LY294002
and wortmannin) for up to 24 h.
Discussion
Binding of IGF-1 to the IGF-1 receptor (type 1 IGFR), a
tyrosine kinase receptor structurally similar to that for
insulin, results in receptor dimerization, autophosphoryla-
tion and activation of several downstream signal transduc-
tion pathways (LeRoith et al. 1995). In endothelial cells,
IGF-1 may be transported intact across the endothelia and
released into the interstitium; however, unlike insulin, a
substantial proportion of IGF-1 that is internalized is
retained within the endothelial cells, where it may exert
biological effects (Bar et al. 1988).
In the present study, we demonstrate that IGF-1 increases
glucose transport into retinal endothelial cells in culture
(Figs 1a and b). This enhancement is similar to that recently
reported for VEGF, another growth factor involved in retinal
development and in pathological states, such as diabetic
retinopathy (Sone et al. 2000). Stimulation of glucose
transport by IGF-1 is not a non-speci®c cellular response to
growth factors per se, since insulin, which is a major
mitogenic factor in the developing central nervous system
(Knusel et al. 1990) and which has a high degree of amino
acid homology to IGF-1 (Jones and Clemmons 1995), does
not stimulate glucose transport in endothelial cells (Betz
et al. 1983; Pekala et al. 1990). Furthermore, retinal
endothelial cell glucose transport is mediated via GLUT1
(Harik et al. 1990; Takata et al. 1990; Mantych et al. 1993;
Kumagai et al. 1994), which is known to be insensitive to
insulin (Mueckler 1994).
IGF-1-stimulated glucose transport into retinal micro-
vascular endothelial cells is mediated by PKC, and in
Fig. 4 Effects of IGF-1 on GLUT1 expres-
sion in BREC cultures. (a, left) Representa-
tive western blot of control cultures (Cont.)
and cultures treated with 25 ng/mL IGF-1
for 24 h (IGF1). Western blotting analysis
was performed on 25-mg aliquots of solubi-
lized whole cell BREC lysates. Blots were
reacted with a polyclonal antiserum raised
against puri®ed human erythrocyte glucose
transporter and developed using a horse-
radish peroxidase-conjugated secondary
antibody and a chemiluminescence system.
(a, right) Representative quanti®cation of
western blots for control and IGF-1-treated
BREC cultures. n  3±6 in each western
blot. Western blotting was performed three
times on different cell cultures with compar-
able results. (b) Representative northern
blot of control cultures (C) and cultures
treated with IGF-1 (25 ng/mL) for the indi-
cated time periods (in hours). Each GLUT1
northern blot was normalized for actin, and
quanti®cation was performed on three
northern blots of identically treated cultures.
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particular, PKC-b. The requirement of PKC in mediating the
effects of IGF-1 on glucose transport into the retinal
endothelial cells is demonstrated by the complete inhibition
of transport after treatment with a variety of general and
PKC-b-selective inhibitors (Figs 2b±d). These effects on
glucose transport are similar to those of VEGF, which also
stimulates BREC glucose transport via stimulation of the b
isoform of PKC (Sone et al. 2000). PI3 kinase is also
necessary for mediating the effects of IGF-1 on BREC
glucose transport, because treatment with two structurally
unrelated inhibitors of PI3 kinase, wortmannin and
LY294002, abolishes the effects of IGF-1 on 2DG uptake
(Figs 3b and c). PI3 kinase and PKC activation by IGF-1 in
BREC occur in a sequential, rather than parallel manner,
since inhibition of either PI3 kinase or PKC alone results in
complete abrogation of IGF-1 stimulated enhancement of
BREC glucose transport. As seen in Fig. 7, inhibition of PI3
kinase by wortmannin abolishes the ability of IGF-1 to
stimulate PKC activity and, in contrast, inhibition of PKC
by GF 109203X has no effect on IGF-1 stimulation of PI3
kinase (Figs 7a and b). Together, these data suggest that
PKC is downstream from PI3 kinase in the signaling
pathways regulating IGF-1 actions in retinal endothelial
cells. In this regard, both insulin and IGF-1 stimulate
activity of PI3 kinase and PKC in a sequential manner in rat
adipocytes; however, in these cells, PI3 kinase stimulates
phosphorylation of another PKC isoform, PKC-z (Valverde
et al. 1996; Standaert et al. 1997). IGF-1 is also known to
activate other signaling pathways, such as mitogen-activated
protein (MAP) kinase, in a variety of cell types (Petley et al.
1999); however, it is not known whether other signaling
pathways participate in the effects of IGF-1 on glucose
transport and proliferation in retinal endothelial cells.
IGF-1 enhancement of BREC glucose transport does not
occur via an increase in total cellular GLUT1 glucose
transporter expression. At concentrations shown to increase
glucose transport (25 ng/mL, Fig. 1a), treatment with IGF-1
for 24 h had no effect on total cellular GLUT1 protein
(Fig. 4a), and exposure to IGF-1 for various time periods up
to 24 h failed to result in an increase the abundance of
GLUT1 mRNA in BREC cultures (Fig. 4b). The increase in
glucose transport in the absence of increased total cellular
GLUT1 abundance is similar to the effects of IGF-1 on
mesangial cell glucose transport (Heilig et al. 1997) and is
also reminiscent of the effects of VEGF on primary BREC
cultures (Sone et al. 2000). Exposure to VEGF (50 ng/mL
up to 24 h) failed to increase total cellular GLUT1 protein
Fig. 5 Thymidine incorporation in BREC cultures. (a) Effects of
IGF-1. Representative thymidine incorporation assay in control cul-
tures (0) and in cultures exposed to increasing concentrations of
recombinant IGF-1. BREC were plated in identical densities, and
after achieving approximately 60% con¯uence, the cultures were
serum deprived overnight and subsequently treated with the appro-
priate concentration of IGF-1. Incorporation of [3H]thymidine was
measured as described in Materials and methods. (b) Effects of gen-
eralized PKC inhibition on IGF-1-stimulated thymidine incorporation.
BREC cultures treated without (±) or with 25 ng/mL IGF-1 for 24 h
were exposed to increasing concentrations of the PKC-speci®c inhi-
bitor, GF 109203X. *p , 0.0001 compared with control. (c) Effects
of selective PKC-b inhibition on IGF-1-stimulated thymidine Incor-
poration. Control (±) and IGF-1-treated (25 ng/mL, 24 h) cultures
were exposed to LY379196 at general PKC (600 nM) or PKC b-
selective (30 nM) inhibitory concentrations. *p , 0.0001 compared
with control; ²p  not signi®cantly different from control; ³p  not
signi®cantly different compared with IGF-1 alone
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and transcript, despite an increase in glucose transport of
approximately 70% under identical conditions (Sone et al.
2000). In the case of VEGF, quantitative western blotting
of plasma membrane fractions from control and VEGF-
treated BREC cultures revealed a comparable increase in
plasma membrane GLUT1 (Sone et al. 2000). These
observations suggest that VEGF stimulates BREC glucose
transport by causing translocation of pre-existing cytosolic
transporters to the plasma membrane, where the transporters
are available for mediating glucose uptake (Sone et al.
2000). Although not directly investigated in the present
study, one may speculate that the effects of IGF-1 on
increasing glucose transport in BREC cultures involve a
process of translocation similar to that of VEGF. This
speculation is strengthened by the observation that both
VEGF and IGF-1 increase BREC glucose transport to
similar magnitudes and do so via activation of PKC-b
(Sone et al. 2000 and this study). We cannot, however, rule
out the possibility that IGF-1 increases the af®nity of
GLUT1 for its substrate.
Similar to its effects on glucose transport, the mitogenic
effects of IGF-1 on retinal endothelial cells are mediated by
PKC kinase and PI3 kinase. As in the case of glucose
transport, both PKC and PI3 kinase appear to be required
for IGF-1-stimulated BREC proliferation, since use of
inhibitors for either PKC or PI3 kinase result in abrogation
of IGF-1 effects on thymidine incorporation (Figs 5 and 6).
Nonetheless, the pathways mediating glucose transport and
proliferation in retinal endothelial cells are not identical.
While inhibition of the b isoform of PKC abolishes IGF-1-
stimulated glucose transport, it has no effect on IGF-1-
stimulated thymidine incorporation (compare Figs 2d and
5c). Taken together, these data suggest that while PI3 kinase
mediates the effects of IGF-1 on both glucose transport and
proliferation in retinal endothelial cells, the effects of IGF-1
on these critical cellular processes are mediated by different
isoforms of PKC. Among typical, calcium-dependent PKC
Fig. 7 Effects of IGF-1 on BREC PKC and PI3 kinase activity:
effects of cross-inhibition. (a) PKC activity assay on permeabilized
control and IGF-1-treated BREC cultures in the presence and
absence of the PI3 kinase inhibitor, wortmannin (100 nM). PKC
assay was performed as described in Materials and methods. Graph
represents the mean and SE of three different experiments, each
performed in duplicate. *p  0.017, p not signi®cant compared with
control. (b) Representative PI3 kinase assay on control and IGF-1
treated BREC cultures in the presence and absence of the PKC inhi-
bitor, GF 109203X (5 mM). The migration of the PI3P standard is
noted on the right. The PI3 kinase assay was performed as
described in Materials and methods and was repeated twice on dif-
ferent BREC cultures with identical results.
Fig. 6 Effects of inhibition of PI3 kinase on IGF-1-mediated BREC
thymidine incorporation. (a) Treatment of control (±) and IGF-1 (1)
cultures with the PI3 kinase inhibitor, wortmannin (100 nM).
*p , 0.0001 compared with control; p not signi®cant compared with
control; ²p , 0.01 compared with control. (b) Treatment of control
(±) and IGF-1 (1) cultures with the PI3 kinase inhibitor, LY294002
at increasing concentrations. *p , 0.0001 compared with control;
²p not signi®cant compared with control; ³p , 0.02 compared with
control; §p , 0.001 compared with control.
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isoforms, a and bII, have been identi®ed in BREC cell
cultures, whereas bI and d have not been detected (Shiba
et al. 1993). Presumably, the a isoform mediates IGF-1-
stimulated BREC proliferation, since generalized inhibition
of calcium-dependent isoforms of PKC with LY379196 at
600 nm, but not selective inhibition of the b isoform of PKC
at 30 nm, abolishes the effects of IGF-1 on BREC thymidine
incorporation (Fig. 5c). The lack of effect of the PKC
b-selective inhibitor on IGF-1-stimulated thymidine incor-
poration in BREC suggests an important difference between
the actions of IGF-1 and those of VEGF in stimulating
endothelial cell proliferation: while both involve PI3 kinase
(Yu and Sato 1999, and this study), the mitogenic actions of
VEGF are mediated by PKC-b, while those of IGF-1 are
mediated through a non-b PKC isoform (Fig. 5c).
In summary, the present study demonstrates that IGF-1
enhances two essential processes within retinal endothelial
cells, i.e. glucose transport and DNA synthesis, via path-
ways involving PKC and PI3 kinase; however, IGF-1 does
so through different PKC isoforms. In normal physiology,
the modulation of both endothelial cell proliferation and
glucose transport by IGF-1 ensures delivery of an essential
metabolic substrate to the developing neuroretina. In
addition, we propose that by increasing glucose ¯ux into
the retinal endothelial cell, the elevated intravitreal IGF-1
concentrations seen in diabetic retinopathy may increase
intracellular glucose and exacerbate its toxic effects on the
retinal microvasculature (Kumagai 1999).
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